BMY

Bristol-Myers Squibb Company

HealthcareDrug Manufacturers - GeneralNASDAQ

$57.18

-$2.28 (-3.98%)today

Conviction

0/ 10

Fair Value$62.72

Upside+9.69%

Signal0

Market Cap$119.7B

52W Range$42.52–$62.89

Next EarningsApr 30

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$61.93

Current Price$58.54

Upside / Down+5.8%

P(Undervalued)60.9%

P(20%+ Up)25.3%

P(15%+ Down)14.5%

Fair Value Distribution — percentile bands

60.9% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

0.7%/yr

±3.7% · revenue growth to justify current price

FCF-Based Reverse DCF

-3.0%/yr

±2.5% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Quick Take

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Trailing P/E16.8x

Forward P/E9.5x

P/S2.5x

EPS (TTM)$3.46

Analyst Target$62.72

Analyst Upside9.7%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 1

Conviction: unchanged

BMY 10-K FY2025: LOE Cliff + Growth Portfolio Execution

BMY at a structural inflection: 2026 is the trough year as Eliquis goes to Medicaid-free + IRA MFP (Medicare), Revlimid hits full generic competition Jan 31 2026. Revenue was flat FY2025 at .2B vs .3B...